INCYTE CORPORATION Advertising Expense
INCYTE CORPORATION (INCY) reported Advertising Expense of $155.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AdvertisingExpense · last filed 2026-02-10
- INCYTE CORPORATION advertising expense for the quarter ending 2021-12-31 was $34.00M, a 174.19% increase year-over-year.
- INCYTE CORPORATION advertising expense for the quarter ending 2021-09-30 was $13.70M, a 114.06% increase year-over-year.
- INCYTE CORPORATION advertising expense for the quarter ending 2021-06-30 was $7.50M, a 41.51% increase year-over-year.
- INCYTE CORPORATION advertising expense for the quarter ending 2021-03-31 was $10.80M, a 125.00% increase year-over-year.
- INCYTE CORPORATION advertising expense for fiscal 2025 was $155.90M, a 22.32% decline from fiscal 2024.
- INCYTE CORPORATION advertising expense for fiscal 2024 was $200.70M, a 9.55% decline from fiscal 2023.
- INCYTE CORPORATION advertising expense for fiscal 2023 was $221.90M, a 12.98% increase from fiscal 2022.
- INCYTE CORPORATION advertising expense for fiscal 2022 was $196.40M, a 197.58% increase from fiscal 2021.
| Period end | Advertising Expense 3 month | Advertising Expense 6 month | Advertising Expense 9 month | Advertising Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $155.90M 10-K · filed 2026-02-10 | |||
| 2024-12-31 | $200.70M 10-K · filed 2026-02-10 | |||
| 2023-12-31 | $221.90M 10-K · filed 2026-02-10 | |||
| 2022-12-31 | $196.40M 10-K · filed 2025-02-10 | |||
| 2021-12-31 | $34.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $47.70M derived: sum of 2 quarters · filed 2024-02-13 | $55.20M derived: sum of 3 quarters · filed 2024-02-13 | $66.00M 10-K · filed 2024-02-13 |
| 2021-09-30 | $13.70M 10-Q · filed 2021-11-02 | $21.20M derived: sum of 2 quarters · filed 2021-11-02 | $32.00M 10-Q · filed 2021-11-02 | $44.40M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-06-30 | $7.50M 10-Q · filed 2021-08-03 | $18.30M 10-Q · filed 2021-08-03 | $30.70M derived: sum of 3 quarters · filed 2023-02-07 | $37.10M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-03-31 | $10.80M 10-Q · filed 2021-05-04 | $23.20M derived: sum of 2 quarters · filed 2023-02-07 | $29.60M derived: sum of 3 quarters · filed 2023-02-07 | $34.90M derived: sum of 4 quarters · filed 2023-02-07 |
| 2020-12-31 | $12.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $18.80M derived: sum of 2 quarters · filed 2023-02-07 | $24.10M derived: sum of 3 quarters · filed 2023-02-07 | $28.90M 10-K · filed 2023-02-07 |
| 2020-09-30 | $6.40M 10-Q · filed 2021-11-02 | $11.70M derived: sum of 2 quarters · filed 2021-11-02 | $16.50M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $5.30M 10-Q · filed 2021-08-03 | $10.10M 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | $4.80M 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | $15.30M 10-K · filed 2022-02-08 | |||
| 2018-12-31 | $10.60M 10-K · filed 2021-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |